Bispecific antibodies have become component in the arsenal of treatments for hematologic malignancies; management of their side effects is crucial to their success.

Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis ...